Anticoagulation options for low platelets with cancer blood clots
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have active cancer (diagnosed/treated in the last 6 months or currently worsening/returning).
- You had a confirmed deep blood clot (like DVT or pulmonary embolism) within the last 14 days, and your doctors plan to treat it with full-dose blood thinners.
- Your platelet count is under 50,000 while you’re having cancer or cancer treatment (or due to it).
- You can sign consent paperwork to join the study.
- You have not already been on blood thinners for this same clot while your platelets were under 50,000 for more than 72 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
This study uses a special blood test to create a score that predicts bleeding risk in patients with blood cancers and very low platelet counts. It could help doctors decide if you need extra care to prevent bleeding.
This study looks at platelet transfusions—how they’re used and whether platelets function well—for people with blood cancers who have low platelet counts. It may help improve transfusion care for people who need platelet support.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
Hear when a new Cancer-associated Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.